Safety of the Anti-CD19 antibody Tafasitamab in Long Term Responders from A Phase II Trial for Relapsed Lymphoma

Tilch, MK; Robak, T; Ghiggi, C; Wuff, E; Herold, S; Theobald, M; Hess, G

Hess, G (通讯作者)，Johannes Gutenberg Univ Mainz, Dept Hematol Oncol & Pneumol, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Rhineland Palat, Germany.;Hess, G (通讯作者)，Johannes Gutenberg Univ Mainz, Univ Canc Ctr, Univ Med Ctr, Langenbeckstr 1, D-55131 Mainz, Rhineland Palat, Germany.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022; 22 (4): 270

Abstract

Novel therapy options are needed for patients with relapsed or refractory lymphoma. The anti CD19 antibody tafasitamab has showed promising efficacy i......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索